Die neuen WHO-Empfehlungen für schnelle Diagnostik und Therapie resistenter Tuberkulose in Deutschland, Österreich und der Schweiz

Zusammenfassung

Die erfreulicherweise zunehmende Evidenz hat in den letzten Jahren mehrfache Änderungen der internationalen Empfehlungen für die Diagnostik und Therapie der resistenten Tuberkulose notwendig gemacht. In diesem Jahr hat die WHO umfassende Empfehlungen veröffentlicht, die die Entwicklungen der letzten Jahre berücksichtigen. Die aktuelle deutsche Tuberkuloseleitlinie erschien im Jahr 2017 und weicht in einigen Bereichen von diesen Empfehlungen ab. Hier werden die Neuerungen der WHO-Empfehlungen von 2020 für schnelle Diagnostik und die Therapie resistenter Tuberkulose zusammengefasst und relevante Abweichungen für Deutschland, Österreich und die Schweiz kommentiert. Eine Neubewertung der Literatur findet derzeit im Rahmen der Aktualisierung der deutschsprachigen AWMF-2k-Leitlinie statt.

Abstract

The increasing evidence has made it necessary to change international recommendations for the diagnosis and treatment of resistant tuberculosis repeatedly in the recent years. This year, the WHO has published comprehensive recommendations that take into account these developments. The current German tuberculosis guideline was published in 2017 with differing recommendations in some areas. Here the new WHO recommendations of 2020 for rapid diagnosis and therapy of resistant tuberculosis are summarized and the relevant differences are commented for Germany, Austria and Switzerland. A complete re-evaluation of the literature is currently taking place by updating the German-language AWMF 2k guidelines.

Publication History

Article published online:
17 November 2020

• Literatur

• 1 Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on Tuberculosis Notification, South Korea. Emerg Infect Dis 2020; DOI: 10.3201/eid2610.202782.
• 2 Stop TB Partnership. The potential impact of COVID-19 response on tuberculosis in high burden countries: a modelling analysis. 2020 Available at: http//wwwstoptborg/assts/documents/news/Modelling%20Report_1%20May%202020_Finalpdf
• 3 Lange C, Dheda K, Chesov D. et al. Management of drug-resistant tuberculosis. Lancet 2019; 394: 953-966 DOI: 10.1016/s0140-6736(19)31882-3.
• 4 Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
• 5 WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organisation; 2019
• 6 WHO Consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organisation; 2020
• 7 WHO Operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organisation; 2020
• 8 Otto-Knapp R, Häcker B, Bauer T. et al. Tuberkulose – Die neuen WHO-Empfehlungen für schnelle Diagnostik und Behandlung. InFo Pneumologie & Allergologie 2020; 3: 6-11
• 9 Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2018. Berlin: Robert Koch-Institut; 2019
• 10 Brodhun B. Epidemiologie der Tuberkulose in Deutschland. Vortrag Tuberkulosetagung 18.03.2019. Berlin:
• 11 Olaru ID, Heyckendorf J, Andres S. et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1700742 DOI: 10.1183/13993003.00742-2017.
• 12 Heyckendorf J, van Leth F, Kalsdorf B. et al. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur Respir J 2018; 51: 1702122 DOI: 10.1183/13993003.02122-2017.
• 13 Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2019. Berlin: Robert Koch-Institut; 2020
• 14 Jahresbericht 2018, Nationale Referenzzentrale für Tuberkulose. Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES); 2019
• 15 Mase SR, Ramsay A, Ng V. et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11: 485-495
• 16 WHO Operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organisation; 2020
• 17 WHO Consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organisation; 2020
• 18 Broger T, Sossen B, du Toit E. et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. The Lancet Infectious diseases 2019; 19: 852-861 DOI: 10.1016/s1473-3099(19)30001-5.
• 19 Tostmann A, Kik SV, Kalisvaart NA. et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008; 47: 1135-1142 DOI: 10.1086/591974.
• 20 Schaberg T, Bauer T, Brinkmann F. et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 2017; 71: 325-397 DOI: 10.1055/s-0043-105954.
• 21 Lange C, Aarnoutse RE, Alffenaar JWC. et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23: 645-662 DOI: 10.5588/ijtld.18.0622.
• 22 Otto-Knapp R, Bös L, Schönfeld N. et al. Resistance to second-line drugs in migrants with multidrug-resistant tuberculosis in the Berlin region. Pneumologie 2014; 68: 496-500 DOI: 10.1055/s-0034-1377226.
• 23 Allix-Beguec C, Arandjelovic I, Bi L. et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med 2018; 379: 1403-1415 DOI: 10.1056/NEJMoa1800474.
• 24 Feuerriegel S, Kohl TA, Utpatel C. et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex®-MycTB. Eur Respir J 2020; DOI: 10.1183/13993003.01796-2020. [Online ahead of print]
• 25 Public Health England National Infection Service. National Mycobacterium Reference Service South (NMRS South). User Handbook. 2019
• 26 Galagan JE. Genomic insights into tuberculosis. Nat Rev Genet 2014; 15: 307-320 DOI: 10.1038/nrg3664.
• 27 Nikolayevskyy V, Kranzer K, Niemann S. et al. Whole genome sequencing of Mycobacterium tuberculosis for detection of recent transmission and tracing outbreaks: A systematic review. Tuberculosis 2016; 98: 77-85 DOI: 10.1016/j.tube.2016.02.009.
• 28 Merker M, Kohl TA, Niemann S. et al. The Evolution of Strain Typing in the Mycobacterium tuberculosis Complex. Advances in experimental medicine and biology 2017; 1019: 43-78 DOI: 10.1007/978-3-319-64371-7_3.
• 29 Heyckendorf J, Andres S, Köser CU. et al. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 2018; 62: e01550-17 DOI: 10.1128/aac.01550-17.
• 30 Meehan CJ, Goig GA, Kohl TA. et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol 2019; 17: 533-545 DOI: 10.1038/s41579-019-0214-5.
• 31 WHO Treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organisation; 2018
• 32 Fregonese F, Ahuja SD, Akkerman OW. et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory medicine 2018; 6: 265-275 DOI: 10.1016/s2213-2600(18)30078-x.
• 33 Weiner M, Burman W, Luo CC. et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrobial agents and chemotherapy 2007; 51: 2861-2866 DOI: 10.1128/aac.01621-06.
• 34 Nijland HM, Ruslami R, Suroto AJ. et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-1007 DOI: 10.1086/521894.
• 35 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-854 DOI: 10.1007/s40265-014-0222-8.
• 36 Ahmad N, Ahuja SD, Akkerman OW. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018; 392: 821-834 DOI: 10.1016/s0140-6736(18)31644-1.
• 37 Nahid P, Mase SR, Migliori GB. et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200: e93-e142 DOI: 10.1164/rccm.201909-1874ST.
• 38 WHO Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organisation; 2018
• 39 Maurer FP, Bauer T, Diel R. et al. Gemeinsame Stellungnahme zur neuen Empfehlung der WHO zur Behandlung der multiresistenten und Rifampicin-resistenten Tuberkulose. Pneumologie 2019; 73: 270-273 DOI: 10.1055/a-0880-9987.
• 40 WHO Treatment guidelines for drugresistant tuberculosis – update 2016. Geneva: World Health Organisation; 2016
• 41 Lan Z, Ahmad N, Baghaei P. et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory medicine 2020; 8: 383-394 DOI: 10.1016/s2213-2600(20)30047-3.
• 42 Günther G, van Leth F, Alexandru S. et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerging infectious diseases 2015; 21: 409-416 DOI: 10.3201/eid2103.141343.
• 43 Rapid-communication: key changes to treatment of drug-resistant tuberculosis. Geneva: World Health Organisation; 2019
• 44 Conradie F, Diacon AH, Ngubane N. et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Eng J Med 2020; 382: 893-902 DOI: 10.1056/NEJMoa1901814.
• 45 Working Group on New TB Drugs, Stop TB Partnership. Clinical Pipeline. Im Internet (Stand 18.09.2020): https://www.newtbdrugs.org/pipeline/clinical
• 46 Butov D, Lange C, Heyckendorf J. et al. Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine. Int J Tuberc Lung Dis 2020; 24: 485-491 DOI: 10.5588/ijtld.19.0508.